In this section

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.

Fizazi, K. et al. (2024) Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. Nature Medicine, 30, (doi: 10.1038/s41591-024-02835-9)

[img] Text
319667.pdf - Published Version
Available under License Creative Commons Attribution.
483kB

Item Type:Articles
Additional Information:Publisher Correction of "First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial", published in Nature Medicine 30: 257-264.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Jones, Professor Robert
Authors: Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., De Giorgi, U., Joung, J. Y., Fong, P. C.C., Voog, E., Jones, R. J., Shore, N. D., Dunshee, C., Zschäbitz, S., Oldenburg, J., Ye, D., Lin, X., Healy, C. G., Di Santo, N., Laird, A. D., Zohren, F., and Agarwal, N.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Nature Medicine
Publisher:Nature Research
ISSN:1078-8956
ISSN (Online):1546-170X

University Staff: Request a correction | Enlighten Editors: Update this record

Deposit and Record Details